Common expression of a tumor necrosis factor resistance mechanism among gynecological malignancies
- PMID: 2289205
- PMCID: PMC11038370
- DOI: 10.1007/BF01754210
Common expression of a tumor necrosis factor resistance mechanism among gynecological malignancies
Abstract
The efficacy of tumor necrosis factor alpha (TNF alpha) as an anticancer agent is limited. This limitation might be related to the expression of a protein-synthesis-dependent resistance mechanism that prevents the lysis of tumor cells by TNF alpha. To test this possibility eight randomly selected human cell lines, three derived from ovarian carcinomas and five derived from cervical carcinomas, were tested for their in vitro sensitivity to TNF alpha-mediated lysis. The results of this analysis showed that all eight cell lines are normally resistant to lysis by TNF alpha. However, in the presence of inhibitors of protein synthesis, seven of them showed a significant increase in TNF alpha-mediated lysis. Measurement of protein synthesis showed that there is a linear correlation between the level of inhibition of protein synthesis and the level of TNF alpha-mediated lysis. The fact that seven of eight randomly selected cell lines are resistant to TNF alpha because they express a protein-synthesis-dependent resistance mechanism suggests that this mechanism of resistance may be common among gynecological cancers. The results also suggest that a therapy involving TNF alpha and inhibitors of protein synthesis might be useful for the treatment of gynecological malignancies.
Similar articles
-
Inhibition of protein synthesis enhances the lytic effects of tumor necrosis factor alpha and interferon gamma in cell lines derived from gynecological malignancies.Cancer Immunol Immunother. 1991;33(3):183-8. doi: 10.1007/BF01756140. Cancer Immunol Immunother. 1991. PMID: 1904315 Free PMC article.
-
Resistance to cytolysis by tumor necrosis factor alpha in malignant gynecological cell lines is associated with the expression of protein(s) that prevent the activation of phospholipase A2 by tumor necrosis factor alpha.Cancer Res. 1992 Feb 15;52(4):866-72. Cancer Res. 1992. PMID: 1737348
-
Cycloheximide-induced modulation of TNF-mediated cytotoxicity in sensitive and resistant ovarian tumor cells.Cancer Chemother Pharmacol. 1990;26(1):1-8. doi: 10.1007/BF02940285. Cancer Chemother Pharmacol. 1990. PMID: 2322985
-
Synergistic effect of tumor necrosis factor-alpha- and diphtheria toxin-mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines.J Immunol. 1991 Oct 15;147(8):2609-16. J Immunol. 1991. PMID: 1918981
-
Expression of a resistance mechanism in ovarian and cervical carcinoma cells prevents their lysis by gamma-interferon.Cancer Res. 1990 Aug 15;50(16):4923-8. Cancer Res. 1990. PMID: 2116222
Cited by
-
Mechanisms involved in Korean mistletoe lectin-induced apoptosis of cancer cells.World J Gastroenterol. 2007 May 28;13(20):2811-8. doi: 10.3748/wjg.v13.i20.2811. World J Gastroenterol. 2007. PMID: 17569116 Free PMC article.
-
Inhibition of protein synthesis enhances the lytic effects of tumor necrosis factor alpha and interferon gamma in cell lines derived from gynecological malignancies.Cancer Immunol Immunother. 1991;33(3):183-8. doi: 10.1007/BF01756140. Cancer Immunol Immunother. 1991. PMID: 1904315 Free PMC article.
-
The PtdIns 3-kinase/Akt pathway regulates macrophage-mediated ADCC against B cell lymphoma.PLoS One. 2009;4(1):e4208. doi: 10.1371/journal.pone.0004208. Epub 2009 Jan 16. PLoS One. 2009. PMID: 19148288 Free PMC article.
References
-
- Aggarawal BB, Moffat B, Harkins RN. Human lymphotoxin. J Biol Chem. 1984;259:686. - PubMed
-
- Blick M, Sherwin SA, Rosenblum M, Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res. 1987;47:2986. - PubMed
-
- Collins JL, Kao M-S, Patek PQ. Humans express natural cytotoxic (NC) cell activity that is similar to murine NC cell activity. J Immunol. 1987;138:4180. - PubMed